---
title: Phase IIa Results Announced for Psoriasis Treatment
description: Phase IIa Results Announced for Psoriasis Treatment
---

[News ](https://www.yourway.com/news)

# [Phase IIa Results Announced for Psoriasis Treatment](https://www.yourway.com/news/phase-iia-results-announced-for-psoriasis-treatment)

 Written by [Yourway](https://www.yourway.com/news/author/yourway) | January 6, 2020

DURECT Corporation announced top-line results from its phase IIa clinical trial of DUR-928 for mild to moderate plaque psoriasis. While the drug was well tolerated, it did not demonstrate a meaningful benefit over placebo in the trial, and DURECT will no longer be pursuing this indication, instead focusing on trials of DUR-928 for nonalcoloholic steatohepatitis (NASH). Will our extensive experience with clinical trials, Yourway knows the importance of agile decision making to determine which trials to terminate and which to pursue.

[View full post](https://www.yourway.com/news/phase-iia-results-announced-for-psoriasis-treatment)

```json
{
  "@context" : "http://schema.org",
  "@type" : "BlogPosting",
  "author" : {
    "@type" : "Person",
    "name" : "Yourway"
  },
  "dateModified" : "2020-01-06T10:00:00.306Z",
  "datePublished" : "2020-01-06T10:00:00Z",
  "headline" : "Phase IIa Results Announced for Psoriasis Treatment",
  "image" : {
    "@type" : "ImageObject",
    "height" : 2525,
    "url" : "https://cdn2.hubspot.net/hubfs/5402331/News%20and%20Articles%20Banners/yourway_news_010620.jpg",
    "width" : 5309
  },
  "mainEntityOfPage" : "https://www.yourway.com/news/phase-iia-results-announced-for-psoriasis-treatment",
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject",
      "height" : 60,
      "url" : "/hs/hsstatic/content_shared_assets/static-1.4092/img/default-amp-logo.png",
      "width" : 60
    },
    "name" : "News"
  }
}
```